Lakewood-Amedex Biotherapeutics, Inc. (LABT)
NASDAQ: LABT · Real-Time Price · USD
0.7822
-0.0098 (-1.24%)
At close: Oct 9, 2026, 4:00 PM EDT
0.7704
-0.0118 (-1.51%)
After-hours: Oct 9, 2026, 7:49 PM EDT
Company Description
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States.
The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs.
It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial.
The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025.
Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Lakewood-Amedex Biotherapeutics, Inc.
| Country | United States |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Kelvin Cooper |
Contact Details
Address: 8031 Cooper Creek Blvd., Suite 103 University Park, Florida 34201 United States | |
| Phone | 941 225 2515 |
| Website | lakewoodamedex.com |
Stock Details
| Ticker Symbol | LABT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 2079272 |
| CUSIP Number | 51255A201 |
| ISIN Number | US51255A2015 |
| Employer ID | 20-5274304 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kelvin Cooper Ph.D. | Chief Executive Officer, SVice President of Research and Development and Director |
| Peter F. Ceccacci | Chief Financial Officer and Vice President of Administration |
| Dr. Thomas Balzer M.D., Ph.D. | Chief Medical Officer and SVice President of Clinical Development |
| Tara Endress | Project Manager and Accounting Manager |
| Daniel Kontoh-Boateng | Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 29, 2026 | 8-K | Current Report |
| Sep 24, 2026 | EFFECT | Notice of Effectiveness |
| Sep 18, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 24, 2026 | DRS | [Cover] Draft Registration Statement |
| Aug 17, 2026 | 424B3 | Prospectus |
| Aug 14, 2026 | SCHEDULE 13G | Filing |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 10, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Aug 10, 2026 | DEF 14A | Other definitive proxy statements |
| Aug 6, 2026 | SCHEDULE 13G | Filing |